Identification and characterization of the biomarker in synovial fluid for hyaluronic acid therapy in osteoarthritis

• Main Authors: Shao-Yun Kuo, 郭紹筠
• Other Authors: Chia-Jung Yu
• Format: Others
• Language: en_US
• Published: 2008
• Online Access: http://ndltd.ncl.edu.tw/handle/08712961243561245332

碩士 === 長庚大學 === 基礎醫學研究所 === 96 === Abstract Decreased hyaluronic acid (HA) level in the synovial fluid (SF) is a characteristic of patients with osteoarthritis (OA), chronic cartilage degradation in the knee joint. The intra-articular injection with HA is an accepted therapy for OA. However, the exact regulation of HA treatment is unclear. Compared the expression SF proteome from OA patients who received HA/800 treatment or not (post and pre-HA treatment) may be possible to identify the protein that response to the HA treatment and apply this to prognosis of OA. We used two-dimensional difference gel electrophoresis (2D-DIGE) combined with matrix-assisted laser desorption ionization time of light mass spectrometry (MALDI-TOF) to determine the differentially displayed proteins in human SF. Our results showed that the levels of four proteins and their isoforms in SF were significantly changed in patients under going HA treatment. Fibrinogen β chain degradation products, haptoglobin α/β, and hemoglobin β were decreased in the SF of OA patients who received intra-articular injection of HA, whereas pigment epithelium-derived factor (PEDF) was increased. We used immunoassay to validate the regulations of these candidate proteins in 19 paired OA patients. We found fibrinogen β chain degradation products level in 84% patients (16/19) was down-regulated by 1.97 fold, p < 0.0001; haptoglobin level in 78.9% patients (15/19) was down-regulated by 1.98 fold, p < 0.0001; hemoglobin level in 73.6% patients (14/19) was down-regulated by 3.2 fold, p < 0.0001, and PEDF level in 68 % patients (13/19) was up-regulated by 1.35 fold, p = 0.002. Our results suggest that HA involves in anti-inflammation as well as anti-oxidative activity and to explore the clinical application of HA for degenerative joint diseases.